Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Avita Medical ( (RCEL) ).
On January 5, 2026, AVITA Medical announced that veteran healthcare executive Joe Woody had been appointed as a new non-executive director effective January 1, 2026, while longtime chairman Lou Panaccio retired after more than a decade of service, including his tenure as chairman from July 2014 to August 2025. Woody, a former CEO of Avanos Medical and Acelity Holdings with extensive experience across major med-tech companies and industry association AdvaMed, will serve on all board committees and receive a mix of annual cash compensation and equity grants for his board role, a move that AVITA’s leadership framed as strengthening the board’s strategic and commercial expertise at a pivotal stage in the company’s growth and supporting its focus on long-term value creation for stakeholders as it scales its acute wound care business globally.
The most recent analyst rating on (RCEL) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.
Spark’s Take on RCEL Stock
According to Spark, TipRanks’ AI Analyst, RCEL is a Underperform.
The overall stock score of 39 reflects significant financial challenges and a bearish technical outlook. Financial performance is the most critical factor, with negative margins, high leverage, and cash flow issues. The technical analysis further supports a negative sentiment, with the stock trading below key moving averages and oversold indicators. Valuation metrics are also unfavorable, with a negative P/E ratio. While the earnings call provided some positive developments, they are overshadowed by ongoing financial difficulties.
To see Spark’s full report on RCEL stock, click here.
More about Avita Medical
AVITA Medical, Inc. is a therapeutic acute wound care company focused on delivering transformative solutions to optimize wound healing and accelerate patient recovery. Its flagship RECELL System, approved by the U.S. Food and Drug Administration for thermal burn and trauma wounds, uses a patient’s own skin to create Spray-On Skin Cells for improved clinical outcomes at the point of care. In the U.S., the company also manufactures and has exclusive rights to market, sell, and distribute the PermeaDerm biosynthetic wound matrix and the Cohealyx collagen-based dermal matrix, while internationally the RECELL System is cleared for a range of skin-healing applications in Europe, and, excluding RECELL GO, in Australia and Japan.
Average Trading Volume: 217,001
Technical Sentiment Signal: Sell
Current Market Cap: $105.8M
For an in-depth examination of RCEL stock, go to TipRanks’ Overview page.